Retinoblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published	Pages	Publisher	Report code
Aug 2022	47	Global Markets Direct	ASDR-609038

Published: Aug 2022 - Pages : 47 - Publisher : Global Markets Direct - Report code : ASDR-609038

Aileron Therapeutics Inc
APEIRON Biologics AG
Ascentage Pharma Group International
Canget BioTekpharma LLC
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cothera Bioscience Pty Ltd
Innovation Pharmaceuticals Inc
Oxular Ltd
PepVax Inc
Seneca Therapeutics Inc
Spectocular LLC
Targeted Therapy Technologies LLC
VCN Biosciences SL

Retinoblastoma Treatment Market Size - By Disease Type (Non-hereditary, Hereditary), Disease Stage (Intraocular, Extraocular), Treatment Type (Chemotherapy, Radiation, Surgery, Laser, Cryotherapy), End-user & Global Forecast, 2024 - 2032

This report can be of interest as well:

Retinoblastoma Treatment Market Size - By Disease Type (Non-hereditary, Hereditary), Disease Stage (Intraocular, Extraoc...

Published: December, 2023 | Report code: ASDR-654418